Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response.

Silvia Valtorta, Massimo Moro, Giovanna Prisinzano, Giulia Bertolini, Monica Tortoreto, Isabella Raccagni, Ugo Pastorino, Luca Roz, Gabriella Sozzi, Rosa Maria Moresco

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer heterogeneity makes response to therapy extremely hard to predict. Patient-derived xenografts (PDXs) are a reliable preclinical model that closely recapitulates the main characteristics of the parental tumors and may represent a useful asset for testing new therapies. Here, using PET imaging, we investigated whether lung cancer PDXs reproduce the metabolic characteristics of the corresponding parental tumors. METHODS: We performed longitudinal 18F-FDG PET studies on 9 different PDX groups obtained by implanting primary-cancer fragments harvested from patients into mice. The SUVmax of each PDX was calculated and compared with the SUVmax of the corresponding parental tumor. RESULTS: Tumor growth rate and uptake varied among the different PDXs and confirmed the preservation of individual characteristics. The intragroup reproducibility of PET measurements was good. Furthermore, PDXs from tumors with a higher metabolic rate displayed a rank order of uptake similar to that of the parental tumors. CONCLUSION: PDXs reproduced the glucose metabolism of the parental tumors and therefore represent a promising preclinical model for the early assessment of therapy efficacy.
Original languageUndefined/Unknown
Pages (from-to)42-47
Number of pages6
JournalJournal of Nuclear Medicine
Volume58
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Keywords

  • 18F-FDG PET, lung cancer, patient-derived xenograft, stem cells

Cite this